Get 20M+ Full-Text Papers For Less Than $1.50/day. Subscribe now for You or Your Team.

Learn More →

Regression of liver stiffness after sustained hepatitis C virus (HCV) virological responses among HIV/HCV-coinfected patients

Regression of liver stiffness after sustained hepatitis C virus (HCV) virological responses among... Regression of liver stiffness after sustained hepatitis C virus (HCV) virological responses among HIV/HCV-coinfected patients The ANRS CO13 HEPAVIH Cohort Objective: We assessed the impact of a sustained virological response (SVR) on liver stiffness among HIV/hepatitis C virus (HCV)-coinfected patients enrolled in the ANRS CO13 HEPAVIH cohort. Methods: We studied HIV/HCV-coinfected patients who received at least one dose of any anti-HCV treatment and who had documented SVR status, a pretreatment FibroScan value of at least 7.1 kPa, and at least one posttreatment FibroScan value. The time required to achieve at least a 30% decrease in liver stiffness was analyzed by con- structing Kaplan – Meier curves and using Cox proportional hazards models. Results: Among 98 patients treated for HCV infection with either pegylated interferon along with ribavirin (n¼ 89) or protease inhibitor-based triple therapy (n¼ 9), 53 patients (54%) had an SVR. Median follow-up was 44.6 (interquartile range: 28.8 – 58.9) months. The probability of achieving a 30% decrease in FibroScan values was 51% [95% confidence interval (CI): 39 – 66] in patients with an SVR and 21% in nonresponders (95% CI: 11 – 36) at 1 year, and 74% (61 – 86) and 28% (17 – 44) at http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png AIDS Wolters Kluwer Health

Regression of liver stiffness after sustained hepatitis C virus (HCV) virological responses among HIV/HCV-coinfected patients

AIDS , Volume 29 (14) – Sep 1, 2015

Loading next page...
 
/lp/wolters-kluwer-health/regression-of-liver-stiffness-after-sustained-hepatitis-c-virus-hcv-onL70fACWD

References

References for this paper are not available at this time. We will be adding them shortly, thank you for your patience.

Copyright
Copyright © 2015 Wolters Kluwer Health, Inc. All rights reserved.
ISSN
0269-9370
eISSN
1473-5571
DOI
10.1097/QAD.0000000000000787
pmid
26372388
Publisher site
See Article on Publisher Site

Abstract

Regression of liver stiffness after sustained hepatitis C virus (HCV) virological responses among HIV/HCV-coinfected patients The ANRS CO13 HEPAVIH Cohort Objective: We assessed the impact of a sustained virological response (SVR) on liver stiffness among HIV/hepatitis C virus (HCV)-coinfected patients enrolled in the ANRS CO13 HEPAVIH cohort. Methods: We studied HIV/HCV-coinfected patients who received at least one dose of any anti-HCV treatment and who had documented SVR status, a pretreatment FibroScan value of at least 7.1 kPa, and at least one posttreatment FibroScan value. The time required to achieve at least a 30% decrease in liver stiffness was analyzed by con- structing Kaplan – Meier curves and using Cox proportional hazards models. Results: Among 98 patients treated for HCV infection with either pegylated interferon along with ribavirin (n¼ 89) or protease inhibitor-based triple therapy (n¼ 9), 53 patients (54%) had an SVR. Median follow-up was 44.6 (interquartile range: 28.8 – 58.9) months. The probability of achieving a 30% decrease in FibroScan values was 51% [95% confidence interval (CI): 39 – 66] in patients with an SVR and 21% in nonresponders (95% CI: 11 – 36) at 1 year, and 74% (61 – 86) and 28% (17 – 44) at

Journal

AIDSWolters Kluwer Health

Published: Sep 1, 2015

There are no references for this article.